More Rapid Sleep Onset with Lingual-Spray vs Oral-Tablet Delivery Zolpidem

Raffa, Robert B. and Westfield, Gerwin (2019) More Rapid Sleep Onset with Lingual-Spray vs Oral-Tablet Delivery Zolpidem. Pharmacology & Pharmacy, 10 (07). pp. 329-342. ISSN 2157-9423

[thumbnail of PP_2019073114471362.pdf] Text
PP_2019073114471362.pdf - Published Version

Download (2MB)

Abstract

Insomnia and related sleep disorders (somnipathies) affect a large segment of the population, and result in a significant negative impact on quality of life and reduced or lost productivity. The speed of sleep onset is a critical characteristic of successful pharmacotherapeutic intervention for insomnia. Zolpidem, a non-benzodiazepine benzodiazepine receptor agonist (nBzRA) is widely used to treat insomnia. Although not itself a benzodiazepine (BZD), zolpidem has high binding affinity for the benzodiazepine receptor, which acts as a positive allosteric modulator of the GABAA receptor complex. It therefore increases the neuronal transmembrane influx of Cl- ions, thereby decreasing neuronal excitability and promoting sleep. In this four-way crossover, dose-ranging, multiple-treatment study, a lingual spray formulation of zolpidem was safe and well-tolerated and yielded more rapid pharmacokinetics (mean plasma concentration) and efficacy (visual analog scale and digit symbol substitution test) compared to oral tablets.

Item Type: Article
Subjects: STM One > Chemical Science
Depositing User: Unnamed user with email support@stmone.org
Date Deposited: 17 Feb 2023 10:25
Last Modified: 26 Apr 2025 08:17
URI: http://note.send2pub.com/id/eprint/308

Actions (login required)

View Item
View Item